Arcellx Q1 net loss narrows to $7.2M; collaboration revenue rises to $39.3M

Arcellx, Inc.

2024-Q1 EPS reported -$0.14 revenue$39,256,000

Cash, cash equivalents, and marketable securities of $691.0M as of March 31, 2024; funds operations into 2027.
Collaboration revenue $39.3M, up $21.4M YoY, driven by Kite Pharma agreement amendments.
Net loss of $7.2M vs $27.3M in Q1 2023, an improvement of $20.1M.
R&D expenses $32.3M (down $0.6M YoY); G&A expenses $22.7M (up $7.3M YoY) on higher personnel costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcellx, Inc. reported for the first quarter ended March 31, 2024 results: revenue $39.3 million, net income Net loss was $7.2 million.

Period: for the first quarter ended March 31, 2024
Revenue: $39.3 million
Net income: Net loss was $7.2 million
Result: reported results

Exact text from the filing

million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue were $39.3 million and $17.9 million for the quarters ended March 31, 2024 and 2023, respectively, an increase of $21.4 million. This increase was primarily driven by changes in estimated

View on SEC.gov

1347 earnings releases filed in the last 30 days. Browse all earnings releases →

Arcellx, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-135267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.